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Abstract: Machine Learning research and its application have gained enormous relevance in recent years.
Their usage in medical settings could support patients, increase patient safety and assist health profes-
sionals in various tasks. However, medical data is often sparse, which renders big data analytics methods
like deep learning ineffective. Data synthesis helps to augment small data sets and potentially improves
patient data integrity. The presented work illustrates how Generative Adversarial Networks can be ap-
plied specifically to small data sets for enlarging sparse data. Following a state-of-the-art analysis is
conducted, experimental methods with such networks are documented, which have been applied to three
different data sets. Results from all three sets are presented and take-away messages are summarized.
Concluding, the results’ quality and limitations of the work are discussed.
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Identification of Synthetic Activators of Cancer Cell
Migration by Hybrid Deep Learning
Dominique Bruns+,[a] Erik Gawehn+,[a] Karthiga Santhana Kumar,[b] Petra Schneider,[a]
Martin Baumgartner,[b] and Gisbert Schneider*[a]
Introduction
Machine learning models have become a cornerstone of com-
puter-assisted drug discovery. Among the many different ap-
proaches, neural networks constitute a particularly active field
of research. Deep convolutional neural networks (CNNs) were
initially developed for image recognition and have recently
been adopted by the life sciences,[1, 2] for example, for rapid
and robust microscopic and angiographic image analysis,[3]
and pattern recognition in genome data.[4] CNNs excel at fea-
ture extraction from images, which has been evidenced not
only by great success in computer vision, but also by promis-
ing use in medical imaging and radiotherapy.[1, 2] In this study,
CNN technology was used for ligand-based drug discovery.
The method combines CNN-based pattern recognition with
self-organizing maps (SOMs)[5] for representing molecular struc-
tures as standardized images. The results of a prospective
application provide proof-of-concept for this concept of collab-
orative machine intelligence.[6] The new hybrid deep learning
method enabled the identification of the first-in-class, synthetic
low molecular weight activators of chemokine receptor CXCR4.
The CXCR4 protein is a member of the G protein-coupled
receptor (GPCR) family.[7] Intracellular signaling is triggered by
the endogenous agonist CXCL12, a chemokine protein with a
molecular mass of 8 kDa, and involves both G-protein activa-
tion and the recruitment of b-arrestin with subsequent recep-
tor internalization.[8] CXCR4 can undergo dimerization to form
homodimers or heterodimers with ACKR3, leading to differen-
tial and complex signaling regulation.[9,10] The CXCR4 receptor
is constitutively expressed,[11] plays a key role in HIV infec-
tions[12,13] and has been identified as an anticancer target for
drug discovery. Several CXCR4 antagonists have been pub-
lished[14–16] including the marketed drug plerixafor. However,
finding novel CXCR4 modulators, especially synthetic low-
molecular-weight agonists as tool compounds that mimic the
CXCL12 chemokine, has been proven difficult. Here, we used
hybrid deep learning for virtual screening of a large screening
compound collection to find innovative chemokine receptor
modulators.
Results and Discussion
The first step of the deep learning approach was to develop a
technique for converting chemical structures to two-dimen-
sional images for further processing by the CNN (Figure 1). For
this purpose, we extracted 495827 bioactive compounds with
annotated nanomolar activities from the ChEMBL23 data-
base[17] and represented them in terms of their topological
pharmacophore features (chemically advanced template
search, CATS).[18] This process encoded each molecule as a 210-
dimensional “CATS descriptor” representation. Molecules with
similar CATS descriptors (i.e. , similar topological shape and
pharmacophore features) were then clustered on a two-dimen-
sional grid using Kohonen’s unsupervised SOM algorithm.[19]
Deep convolutional neural networks (CNNs) are a method of
choice for image recognition. Herein a hybrid CNN approach is
presented for molecular pattern recognition in drug discovery.
Using self-organizing map images of molecular pharmaco-
phores as input, CNN models were trained to identify chemo-
kine receptor CXCR4 modulators with high accuracy. This ma-
chine learning classifier identified first-in-class synthetic CXCR4
full agonists. The receptor-activating effects were confirmed by
intracellular cAMP response and in a phenotypic spheroid inva-
sion assay of medulloblastoma cell invasion. Additional macro-
molecular targets of the small molecules were predicted in sili-
co and tested in vitro, revealing modulatory effects on dopa-
mine receptors and CCR1. These results positively advocate
the applicability of molecular image recognition by CNNs to
ligand-based virtual compound screening, and demonstrate
the complementarity of machine intelligence and human
expert knowledge.
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The SOM identifies prototype patterns in the training data and
arranges the resulting data clusters as a neighborhood-preserv-
ing map, where each grid point corresponds to one of the pro-
totype patterns forming the cluster centroids.[20] The resulting
map was used to generate images of the molecular represen-
tations (CATS).[21] Different strategies to leverage the informa-
tion contained in SOM patterns have been proposed.[22,23]
Here, we used a CNN for feature extraction from the SOM
images (Figure 1) and applied the model to ligand-based
virtual compound screening. The trained CNN model predicts
ligand bioactivity based on the SOM excitation patterns
(images) evoked by the input molecular structures.
The motivation to perform deep learning on top of molecu-
lar descriptor encoding and similarity clustering was threefold:
Firstly, there is no best generic representation of a molecule
for drug design.[24] Secondly, combining human and machine
intelligence enables deep learning in low-data situations,
taking advantage of the expert knowledge ingrained in the
CATS descriptor, which is known to enable scaffold hopping in
combination with machine learning.[18] Thirdly, artificial neural
networks are not as flexible as the human mind when it comes
to abstraction from very few input examples.[25] This means
that learning essential known molecular pharmacophore fea-
tures or variants thereof cannot be ensured when the under-
lying ligand data is scarce, as is often the case when one at-
tempts to find compounds against new targets.[26] The method
presented here aims to leverage prior background information
in a semi-supervised fashion and enable deep learning in such
situations.
The machine learning model was developed in two steps.
First, a SOM was trained on a set small bioactive molecules, as
described.[21,27] Then, different CNN classifiers were trained and
tested for their ability to predict CXCR4 ligands, using the
trained SOM model as input layer. The best CNN architecture
contained an input layer with 28V28=784 neurons (i.e. , the
number of SOM clusters), a convolutional layer with a recep-
tive field size of 4V4 pixels, stride=1 and 40 feature maps, fol-
lowed by a pooling layer using max-pooling with a window
size of 2V2 pixels and stride=1, and finally a feedforward layer
with 200 input neurons and two output neurons, one for each
data class (Figure 1). For prospective application, this deep net-
work architecture was trained on all available data (392 CXCR4
modulators) and used for CXCR4 target prediction of the
screening compound pool. (Figure 2, Table 1)
Of the &5.7 million compounds in the screening compound
pool, 7423 were predicted as active against CXCR4 with a net-
work Score >0.995. These potentially active molecules were
Figure 1. Hybrid deep learning architecture. Compounds were represented in terms of CATS pharmacophore descriptors, and converted into SOM images
with a resolution of 28V28 pixels. Coloring (temperature scale) of the map pixels shows the local activation of the prototype pharmacophore patterns learned
by the SOM. These molecular images were used as input to the CNN classifier. The best-performing CNN contained a convolution layer with 40 feature maps,
a max-pooling layer, and a fully connected feedforward classifier with 200+2 neurons. The output value (Score) can be interpreted as the pseudo-probability
of belonging to the positive training set (here: CXCR4 ligands).
Figure 2. Convolutional neural network (CNN) training and prediction score
distribution. A) Development of mean and standard deviation of the Mat-
thews correlation coefficient (MCC, in [@1,1] with MCC=1 indicating perfect
prediction) for the best network architecture during cross-validation (red),
and the MCC for training on the complete CXCR4 data (blue). B) Distribution
of the predicted pseudo-probability of the CNN (Score) obtained for a library
of 5.7 million screening compounds. The top-ranking compounds (Score
>0.995) were considered for bioactivity testing.
Table 1. Statistical evaluation of the deep learning classifier model. Mean
and standard deviation of the Matthews correlation coefficient (MCC),
accuracy, precision, recall and the receiver-operator characteristic area
under the curve (ROCAUC, in [0,1] with ROCAUC=1 indicating perfect
prediction) both in five-fold cross-validation and after training the model
on all CXCR4 data (final model). Results were collected as streaming met-
rics, meaning that they were updated continuously during the learning
process.
Cross-validation Final model
Training data set Validation data set Complete data set
MCC 0.84:0.01 0.88:0.04 0.87
accuracy 0.92:0.01 0.94:0.02 0.93
precision 0.92:0.01 0.93:0.03 0.93
recall 0.92:0.01 0.95:0.02 0.94
ROCAUC 0.92:0.01 0.94:0.02 0.93
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further condensed to a set of 40 purchasable compounds
(Table S1 in the Supporting Information) by four methods:
* Method 1. Ten compounds were selected based on the
overall highest CXCR4 prediction probability of the CNN
(highest network Score). None of these compounds were
predicted as chemokine receptor ligands by SPiDER soft-
ware,[23] an independent tool for target prediction.
* Method 2. Ten compounds were selected based on the
overall most confident chemokine receptor predictions
made by the SPiDER target prediction software.[23]
* Method 3. The 7423 compounds with a CNN Score >0.995
were sorted by decreasing Score values and subjected to
target prediction by SPiDER.[23] From this sorted list, the ten
top-ranking compounds were selected that received SPiDER
predictions as potential chemokine receptor ligands. Their
ranks were between 17 and 95 of the sorted CNN Score list.
* Method 4. A scaffold tree of all 7423 screening compounds
with a CNN Score >0.995 was generated. The subtrees con-
taining the compounds selected by Methods 1, 2, and 3
were excluded. The remaining ten largest subtrees were pri-
oritized and the compounds from each subtree were sorted
according to their CNN Score. From each of the ten subtrees
the highest ranking molecule was selected which possessed
a framework extending the scaffold diversity of the com-
pounds selected by Methods 1, 2, and 3.
In total, 36 of the 40 selected compounds could be pur-
chased from commercial suppliers and biologically tested. Five
of the tested compounds showed an EC50 below 50 mm in cell-
based CXCR4-cAMP assays (Table 2, Figure S1). Compared with
the endogenous agonist CXCL12 (EC50=0.31–0.34 nm), these
observed activities are weak (Figure S2). However, the effect of
the most potent ligand (1, EC50=16–18 mm) had a maximal ag-
onistic effect of 128% in the cAMP assay, which is stronger
than the intracellular cAMP response evoked by CXCL12
(Figure 3). Cancer cell migration was significantly stimulated by
compound 1 (p<0.0001, Kruskal–Wallis test, Figure 4b). Super-
agonist 1 features a clover-like molecular structure of three ar-
omatic rings arranged around a central positively ionizable ter-
tiary amine. This arrangement of functional groups follows the
“three-finger pharmacophore model” of protein–protein inter-
action (PPI) inhibitors.[28] Apparently, the deep learning model
was able to implicitly identify this structural pattern in the
training data. To the best of our knowledge, compound 1 is
the first synthetic low-molecular-weight full CXCR4 agonist re-
ported to date.[29]
Morpholine scaffolds, like in compounds 2 and 3, were pre-
viously identified as CXCR4 antagonists.[30,31] Compounds 2 and
3 were also predicted as chemokine receptor ligands by
SPiDER.[23] Compound 4 is the first CXCR4 modulator contain-
ing the 3,6-diazabicyclo[3.2.2]nonane-6-yl substructure which
had previously been reported for orexin 1 and orexin 2 recep-
tor ligands.[32] Compound 5 features an 6-azaspiro[2.5]octane
scaffold with partial agonistic effects on CXCR4. This scaffold is
not reported in ChEMBL24 as active against any of the chemo-
kine receptors.
Regarding the compound selection method, compound 1
was on rank 11 according to the neural network Score
(Method 1). Compounds 2, 3, and 5 were selected based on
their high SPiDER score, ranging from 0.991 for 5 and 0.996
for 3 (Method 2). Compound 4 was among the top-ranking
Table 2. Compound activities in the cAMP assay performed in CHO cells
overexpressing human CXCR4. CXCR4 activity was tested for cAMP activi-
ty with CXCL12 as positive control and AMD3465 hexahydrobromide as
negative control (N=2).







[a] Approximated value from limited experimental data. Dose–response
curve fitting resulted in the values. Visual inspection of the curve shows
approximation.
Figure 3. Concentration-dependent activation of CXCR4 by CXCL12 and
compound 1 in the cAMP assay. Receptor activation is expressed as the rel-
ative effect compared with the effect of the endogenous ligand CXCL12
(N=2).
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molecules (rank 57) according to the neural network Score that
were also predicted as chemokine receptor ligands by SPiDER
(Method 3). No actives were retrieved based on scaffold diver-
sity (Method 4).
For phenotypic effect screening, the 36 compounds were
tested by a spheroid invasion assay (SIA, Figure 4a, b) using a
cell-based model of sonic hedgehog medulloblastoma tumors,
which express high levels of CXCR4 (Figure S4) and depend on
CXCR4 function for tumor propagation.[33] The SIA revealed a
significant invasion-activating effect of compounds 1 and 3–5
on DAOY medulloblastoma cells (Figure 4c). We then tested
the effect of compounds 1–5 on cells with silenced CXCR4
(Figures 4d and S5). The silenced cells still showed invasion
when stimulated with bFGF which induces cell invasion via a
CXCR4 independent pathway. Comparing 1, 4, and 5 to their
corresponding silencing control shows that invasion was signif-
icantly reduced after 24 hours of incubation. The average inva-
sion in the CXCR4 silenced cells caused by compounds 2 and
3 was statistically insignificant.
There was no correlation between the EC50 values in the
cAMP-based assay and cell migration in the SIA (r2=0.13). To
understand this discrepancy between the results of the func-
tional and the phenotypic assays, alternative modes of action
were considered. To this end, computational target predictions
by SPiDER[23] and TIGER[34] software were obtained for com-
pounds 1–5. Targets with an influence on cell migration or
chemotaxis, according to the respective gene ontology anno-
tation,[35] were considered and their expression on DAOY me-
dulloblastoma cells taken into account (Figure S5). A subset of
target proteins was selected for in vitro testing (Table 3).
All five compounds show activity against the predicted tar-
gets (Table 3). Chemokine receptor CCR1 is a receptor found
on cells of the immune system and plays a role in the signaling
in inflammatory sites.[36] It is part of a larger signaling network,
involving several chemokine ligands that also interact with
other chemokine receptors. Dopamine D1 receptors are GPCRs
that indirectly activate the adenylate cyclase, leading to elevat-
ed intracellular cAMP levels. In terms of downstream effects,
D2 dopamine receptors reduce cAMP levels by inhibiting the
adenylate cyclase.[37] D2 receptors exist as two alternatively
spliced isoforms with different functions, the long isoform
(D2L) and the short isoform (D2S). While D2L acts as a post-
synaptic Gi-coupled receptor,
[38] D2S receptors are presynaptic
and act as D1 autoreceptors.[37] These receptors may also affect
intracellular calcium levels.[39,40]
In particular, D2 dopamine receptor binding with varying
preferences toward the different isoforms was observed. Com-
pound 1 showed D1 and D2S receptor antagonistic effects and
D2L binding. Whether this activity is causative for the observed
effect on DAOY cell migration remains an open question at
this time, because the protein expression in DAOY cells was
performed on the RNA level, and no comment can be made
on the isoform of the D2 receptor that is expressed in these
Figure 4. Spheroid invasion assay (SIA). a) Concept of the assay. Average dis-
tances di (arbitrary units) of cell invasion in the collagen matrix was deter-
mined by automated microscopy image analysis. b) Migration of DAOY cells
after incubation in the presence of the test compounds (concentration:
10 mm) or absence of test compounds (control) after 24 h (N=3). The effects
of compounds 1–5 were compared with the untreated control (**p=0.001–
0.01, ****p<0.0001). Boxplots show the mean (black line), the 1st and 3rd
quartiles (lines), and the 5th and 95th percentiles (whiskers). See SIA with
the endogenous ligand CXCL12 in Figure S3 and evidence for CXCR4 expres-
sion in Figure S4. c) SIA fluorescence microscopy images. d) SIA with CXCR4
knockdown. Invasion of DAOY (control), DAOY with the silencing control
(siControl) and DAOY with silenced CXCR4 (siCXCR4). Incubation in the ab-
sence of a stimulant (control), with bFGF (concentration: 100 ngmL@1]), or
compounds 1–5 (concentration: 10 mm) for 24 h (N=3). The effects were
compared with the corresponding silencing control (*p=0.01–0.05,
****p= <0.0001). Boxplots show the mean (black line), the 1st and 3rd
quartiles (lines), and the 5th and 95th percentiles (whiskers). See evidence
for CXCR4 expression in Figures S5 and S6.
Table 3. Potential targets profiled for compounds 1–5.[a]
Target (assay type) Compound
1 2 3 4 5
CXCR4 (agonist effect) 45–53 40–64 50–57 51–58 8–38
CXCR4 (antagonist effect) <0 <0 <0 <0 <0
CCR1 (agonist radioligand) <0 5–8 59–64 1–2 62–66
D1 (agonist effect) 1–5 <0 <0 <0 <0
D1 (antagonist effect) 49–71 <0 <0 <0 <0
D2L (antagonist radioligand) 99–100 8–17 44–51 22–38 95–97
D2S (agonist effect) 15–22 30 80–114 30–35 45–47
D2S (antagonist effect) 44–50 n.a. n.a. n.a. n.a.
[a] Values are percent (%, N=2) of the respective control. Compounds
were tested at a single concentration of 50 mm for CCR1, D1 (D1 dopa-
mine receptor), D2L (D2(long) dopamine receptor), and at 10 mm on
CXCR4 and D2S (D2(short) dopamine receptor). CXCR4 activity was tested
for cAMP activity with CXCL12 as positive control and AMD3465 hexahy-
drobromide as negative control. CCR1 activity was determined in a radio-
ligand displacement assay with [125I]MIP-1-a. D1 and D2S were assayed in
functional assays. D1 was tested for cAMP activity, with dopamine as pos-
itive control and SCH 23390 as negative control. D2L was tested in an an-
tagonistic radioligand assay using [3H]methylspiperone. D2S was tested in
an impedance assay, with dopamine as positive control and butaclamol
as negative control. Compounds inducing more than 25% agonism on
D2S were unsuitable for antagonism screening. n.a. : not available.
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cells. Compound 2 is a full agonist for CXCR4 according to the
cAMP-based assay. However it did not invoke significant cell
migration in the SIA (Figures 4d and S7). Activity testing re-
vealed compound 2 as a weak D2S agonist, a property it
shares with compounds 3–5. Compounds 3 and 5 were con-
firmed as CCR1 and D2L ligands, with 3 being a stronger D2S
agonist than 5. These newly identified bioactivities showcase
successful computational target prediction for the phenotypic
screening hits.
To determine whether these results of the deep learning ap-
proach justify its computational complexity, we compared the
CNN model to straightforward similarity searching with CATS,
because this molecular representation also provided the input
to the deep learning model. We calculated the Euclidean dis-
tance of each of the 392 known CXCR4 modulators in the
training set to the screening library and sorted the library com-
pounds by decreasing similarity to each reference ligand indi-
vidually. To determine the ranks of the hits 1–5 according to
CATS, we averaged their individual ranks in the 392 sorted lists.
With this similarity approach, compound 1 was found on rank
3634337, compound 2 on rank 2860603, compound 3 on
rank 3021870, and compound 4 on rank 1698982. The great-
est pairwise similarity was calculated for reference CXCR4
ligand IIk[41] and hit compound 3, which was found on average
rank 53. This result suggests that none of the actives 1–5
would have been retrieved by CATS similarity searching alone.
The CNN model enabled meaningful virtual screening and re-
trieved innovative bioactive compounds.
Conclusion
Drug design projects are often confronted with limited data
availability, rendering the straightforward application of data-
driven deep learning unfeasible. In this prospective application,
we explored the usefulness of CNNs to virtual compound
screening in such a situation. To enable the application of
CNNs, we devised a virtual screening workflow combining the
advantages of domain-specific data representation with deep
model learning. This concept of combining two types of neural
networks (SOM and CNN) proved successful for the given task
of identifying novel CXCR4 modulators. Structurally diverse li-
gands were identified in a cell-based assay, and for some of
the hits, a stimulating effect on cancer cell migration was con-
firmed. Model application led to the identification of the first
reported small molecular CXCR4 agonists from a large com-
pound collection. These bioactive compounds would not have
been identified by plain similarity searching with the identical
molecular representation (CATS) used for neural network mod-
eling. Results also suggest that the observed effects of the
compounds on cell migration are not or not exclusively linked
to CXCR4. Preliminary activity testing points to dopamine re-
ceptors playing a role in the regulation of medulloblastoma
cell migration.
Despite these encouraging results, the scope of the current
approach is limited and the concept requires further develop-
ment. Firstly, the model’s high accuracy level in retrospective
cross-validation did not translate to the prospective applica-
tion. This observation is most relevant as it highlights the ne-
cessity of prospective real-world application of deep learning
models in drug discovery. Theoretical retrospective estimations
of a model’s generalization ability might be overly optimistic.
Secondly, the moderate bioactivities of the hit compounds
suggest deficits of the overall modeling concept. Compared
with the endogenous agonist CXCL12, the synthetic com-
pounds are almost 50000-fold less active. However, one
should consider the fact that CXL12 is a protein agonist and
the hit compounds are isofunctional small molecule PPIs. This
discrepancy is not a specific issue of the CNN approach but
frequently observed in virtual screening. Future method devel-
opments will also have to tackle the problem of quantitative
activity prediction.[42,43] However, any data-driven model can
only be prospectively successful when trained with representa-
tive and reasonably accurate data sets that define chemically
meaningful boundaries of the model’s applicability domain. In
the present example, hybrid deep network training was suc-
cessful despite the comparably small number of training exam-
ples.
Experimental Section
Positive dataset: The set of CXCR4 ligands combined activity data
from ChEMBL23,[17] literature sources,[44–49] and compounds from in-
house projects[50] (together the “positive” set). Database entries
were removed that contained ‘the blockade of HIV entry“ as an
assay-endpoint annotation in ChEMBL, and entries without a nu-
meric activity value or without further information on the assay
conducted in the corresponding publications. Activities of different
standard types (IC50, EC50, Ki, EC) were considered. For entries with
several annotated activities, the median of the activities acquired
in binding assays was considered. When several values were given,
EC and values with the relation ’> ’ were excluded and the median
value calculated. Ligands were considered active if the correspond-
ing activity value was lower or equal to 10 mm. In total, the curated
positive dataset consisted of 392 molecules with reported activities
on CXCR4.
Negative dataset: The negative dataset consisted of ligands from
the ChEMBL23 database with non-negative activity comments, had
annotated assay confidence scores >7, had ’Single Protein’ as
target type as well as annotations for standard metrics (IC50, EC50,
Ka,b,d,e,i,m). Ligands annotated with the non-logarithmic activity
values were discarded if they: 1) lacked a unit annotation (‘stan-
dard_units’ is None), 2) were tested in assays with mutated pro-
teins, 3) had a molecular weight <110 gmol@1, and 4) were anno-
tated as CXCR4 ligands. All valid activity data were transformed in
to log10 units. Only ligands with log-activity values between 3 and
12 against targets other than CXCR4 were kept for model develop-
ment. This data processing resulted in 495827 molecules constitut-
ing the negative dataset for CNN training.
Screening library: For virtual compound screening we compiled a
pool consisting of commercially available compounds (Asinex,
Delft, The Netherlands; Chembridge, San Diego, CA, USA; Enamine,
Monmouth Jct. , NJ, USA; Specs, Zoetermeer, The Netherlands) and
an in-house virtual combinatorial library, resulting in a total of
5747961 compounds. Sanitation and standardization of all com-
pounds was performed using MOE 2016.08[51] software. The screen-
ing compounds were encoded as descriptor arrays using CATS2
software[18] prior to CXCR4 target prediction by the hybrid model.
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Convolutional neural network: For the deep learning approach, a
CNN was trained as binary classifier to predict ligands as either
active against CXCR4 or as belonging to the negative dataset. Prior
to feeding data to the CNN, a SOM with 28V28 neurons was used
to cluster all bioactive molecules from ChEMBL22 according to
their similarity in CATS descriptor space.[23] The activation image
generated by each molecule when fed to this trained SOM was
used as input data to the deep CNN implemented with Tensor-
flow.[52] To identify a suitable parameter set for the CNN, a grid-
search over the number of hidden layers (one to three layers),
types of hidden layers (convolutional layer, pooling layer, feedfor-
ward layer) and varying parameters for the different layer types
was performed, resulting in 108 network topologies for evaluation.
Convolutional layers had a receptive field size of 4V4 pixels with a
stride of 1, padded with periodic boundaries. The only variable pa-
rameter of the convolutional layers was the number of filters used
(the convolutional layer’s “depth”), which could be either 40, 50, or
60. A restriction was placed on network architectures containing
several convolutional layers, in that the depth from one convolu-
tional layer to another had to increase. Pooling layers always used
max-pooling with a pooling window size of 2V2 pixels and a
stride of 1. Feedforward layers could contain either 50, 100 or 200
neurons. All layers were trained with rectifier linear unit (ReLU) acti-
vation, apart from the output layer which used softmax activation.
Each architecture was trained for 1000 epochs using fivefold cross-
validation with a 4:1 ratio of training to test data. The different ar-
chitectures were trained using stochastic gradient descent with a
batch size of 256 and a stepwise decaying learning rate, starting at
0.007 with a decay factor of 0.9 every 40 epochs. Because the
number of negative molecules exceeded our positive dataset by
several orders of magnitude, negative subsampling was used for
each fold by using the positive dataset and adding an equally
large, randomly selected amount of ligands from the negative
dataset. Cross-entropy with an L2 regularization factor of 0.01 was
chosen as error function for CNN training, performed with a mo-
mentum (momentum=0.9) optimizer. Among the 108 architectures
tested, the architecture displaying the highest average Matthews
correlation coefficient (MCC)[53] during cross-validation was trained
on all the data and then used for virtual screening of CXCR4 active
ligands in the screening library.
The network models were implemented in Python (2.7) using the
libraries TensorFlow (1.4.0),[52] scikit-learn (0.19.1),[54] scipy (1.0.0),[55]
numpy (1.13.3),[56] matplotlib (2.1.1),[57] and pandas (0.21.0).[58] The
deep-learning calculations were performed on a Linux-computer
(Ubuntu 16.04) with four 3.6 GHz Intel Core i7 6850 K processors
and an ASUS GeForce GTX1080Ti STRIX graphics card. Further cal-
culations and analysis were performed on Macintosh Workstation
(OS X Yosemite, 10.10.5, 2V2.26 GHz Quad-Core Intel Xeon with
48GB memory). MOE 2016.08[50] was used for the standardization
of molecules. Analyses were performed using Python (3.5.3) with
seaborn (0.7.1), matplotlib (2.0.0)[57] Pandas (0.19.3),[58] RDKit
(2016.03.4),[59] and libraries. SPiDER predictions[23] were calculated
using Knime (2.12.02).
In silico target prediction with SPiDER: The SPiDER software pre-
dicts potential targets for given molecule queries.[23] The input mo-
lecular structures were standardized for pH 7 using MOE2016.08.[51]
CATS descriptors[18] and MOE descriptors were calculated and used
as input for SPiDER.[23] Only the target predictions with p values
<0.05 were considered.
Scaffold diversity : The diversity of generated scaffolds was ana-
lyzed using Scaffold Hunter software (scaffold-hunter-2.6.3).[60]
In vitro tests: Compounds selected for testing were ordered from
the respective suppliers and stock concentrations of 10 mm in
DMSO prepared. The stock solutions were used for subsequent
testing.
Functional assay for CXCR4: Functional assessment of the com-
pound was determined by antagonistic and agonistic effect at
10 mm in a cAMP assay. CXCR4 was tested for cAMP activity with
CXCL12 as positive control and AMD 3465 hexahydrobromide as
negative control. Where the efficacy was higher than 50%, dose–
response studies were conducted. The assays were performed by
DiscoverX (Fremont, CA, USA) on a fee-for-service basis.
Silencing CXCR4 using RNA interference: DAOY cells with a conflu-
ence of approximately 75% of total surface area were transfected
with small interference RNA (siRNA) specific for CXCR4 (assay ID:
s15412, Thermofischer Scientifc) or Silencer select negative control
(assay ID: 4390843, Ambion). The siRNAs were used at the final
concentration of 5 nmol. The transfection was facilitated using
DharmaFECT 4 transfection reagent (T-2004-03, Dharmacon). After
48 hours, RNA and proteins were isolated from DAOY cells. The
gene expression and protein expression were determined by qPCR
and Immunoblotting, respectively. Upon successful downregulation
of CXCR4, the transfected cells were used for SIA.
Spheroid invasion assay (SIA): The effect of compounds on cell inva-
sion and the phenotype of the medulloblastoma tumor cell line
were determined. DAOY cells were tested by SIA, as described.[61]
DAOY cells stably expressing lifeact (LA) enhanced green fluores-
cent protein (EGFP) produced by lentiviral transduction with
pLenti-LA-EGFP were used for SIA. In brief, 1000 DAOY LA-EGPF
cells per 100 mL per well were seeded in a 96-well cell-repellent mi-
croplate (650790, Greiner Bio-One). The cells were incubated over-
night at 37 8C to form spheroids. 70 mL of the medium was re-
moved from each well, and remaining medium with spheroid was
overlaid with 2.5% (final concentration) of ice-cold bovine colla-
gen 1 (5005-B, Advanced BioMatrix, San Diego, CA, USA). The colla-
gen was allowed to polymerize for 1 h at 37 8C. Following the poly-
merization of collagen, fresh serum free medium was added to the
cells and then treated with 10 mm (final concentration) of the com-
pounds. The embedded cells were allowed to invade the 3D colla-
gen matrix for 24 h, after which they were fixed with 4% PFA and
stained with Hoechst. Images were acquired on an Axio Observer 2
mot plus fluorescence microscope (Zeiss, Munich, Germany) using
a 5V objective. The extent of cell invasion was determined as the
average of the distance invaded by the cells from the center of the
spheroid, using automated cell dissemination counter.[52]
Screening assays for other targets : Functional assessment of the
compounds was determined at 10 mm. Radioligand displacement
assay with [125I]MIP-1-a was performed for CCR1. D1 and D2S were
assayed in functional assays. D1 was tested for cAMP activity, with
dopamine as positive control and SCH 23390 as negative control.
D2L was tested in an antagonistic radioligand assay using
[3H]methylspiperone. D2S was tested in an impedance assay, with
dopamine as positive control and butaclamol as negative control.
Compounds inducing more than 25% agonism on D2S were un-
suitable for antagonism screening. The assays were performed by
Cerep (Celle l’Evescault, France) on a fee-for-service basis.
Statistical analysis. All statistical analyses were as performed using
Prism v7 on Macintosh (GraphPad Software, La Jolla, CA, USA). Re-
sults of the phenotypic assay were tested on their intrinsic variabil-
ity by one-way ANOVA (Kruskal–Wallis test). Compounds that show
no significant intrinsic variability were compared with the control
using Dunn’s multiple comparisons test.
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